

Roberto Padoan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3523654/publications.pdf>

Version: 2024-02-01

50
papers

413
citations

1039880

9
h-index

794469

19
g-index

51
all docs

51
docs citations

51
times ranked

693
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. <i>Journal of Autoimmunity</i> , 2020, 112, 102502.	3.0	86
2	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	2.9	78
3	Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes. <i>Clinical Rheumatology</i> , 2018, 37, 1075-1083.	1.0	43
4	Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment. <i>Journal of Immunology Research</i> , 2018, 2018, 1-16.	0.9	31
5	Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. <i>Journal of Autoimmunity</i> , 2020, 108, 102397.	3.0	26
6	Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3225-3227.e2.	2.0	23
7	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churgâ€™Strauss syndrome). <i>European Respiratory Journal</i> , 2021, 57, 2004158.	3.1	19
8	Coganâ€™s syndrome: new therapeutic approaches in the biological era. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 781-788.	1.4	13
9	The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). <i>Medicine (United States)</i> , 2016, 95, e5506.	0.4	12
10	Disease and treatment-related morbidity in young and elderly patients with granulomatosis with polyangiitis and microscopic polyangiitis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1441-1448.	1.6	12
11	Fully integrated [18F]FDG PET/MR in large vessel vasculitis. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.4	10
12	Neutrophil infiltrates and eosinophil aggregates in chronic rhinosinusitis with nasal polyps and EGPA. <i>Clinical Rheumatology</i> , 2021, 40, 1949-1957.	1.0	7
13	IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , 2021, 124, 102725.	3.0	7
14	Overall Disability Sum Score for Clinical Assessment of Neurological Involvement in Eosinophilic Granulomatosis With Polyangiitis. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 197-202.	0.5	6
15	No Differences in Nasal Tissue Inflammatory Cells and Adhesion Molecules (iCAM-1 and vCAM-1) Based on the Comparison of EGPA With Eosinophilic Chronic Sinusitis With Polyposis. <i>American Journal of Rhinology and Allergy</i> , 2019, 33, 395-402.	1.0	6
16	Nasal polyps in eosinophilic granulomatosis with polyangiitis: Structured histopathology and CD105 expression. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2020, 41, 102661.	0.6	5
17	Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis. <i>Autoimmunity Reviews</i> , 2022, 21, 103018.	2.5	5
18	Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 107-113.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Diagnostic and prognostic role of renal histopathology in rheumatic diseases. <i>Reumatismo</i> , 2018, 70, 165-177.	0.4	3
20	Ear, nose, and throat in ANCA-associated vasculitis: a comprehensive review. , 0, , .		3
21	Health-Related Quality of Life in Patients With ANCA-Associated Vasculitis and Sinonasal Involvement. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e89-e94.	0.5	2
22	The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis. <i>Reumatismo</i> , 2021, 73, .	0.4	2
23	Biologic therapy in relapsing polychondritis: navigating between options. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 661-671.	1.4	2
24	Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study. <i>Rheumatology</i> , 2022, 62, 341-346.	0.9	2
25	FRI0387â€¦Peripheral Neuropathy in Eosinophilic Granulomatosis with Polyangiitis (EGPA). Incat Disability Score To Evaluate Damage and To Predict Long Term Outcome in 50 Patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 574.3-575.	0.5	1
26	107.â€¢FULLY INTEGRATED 18F-FDG PET/MR IN LARGE VESSEL VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	1
27	Whippleâ€™s aortitis. <i>Rheumatology</i> , 2022, , .	0.9	1
28	Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 188-194.	0.4	1
29	Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 107-113.	0.4	1
30	FRI0178â€¦Anti-Etanercept Antibodies and Etanercept Leves Levels in Rheumatoid Arthritis Patients Treated with Low and Full-Dose Etanercept in Das28 Remission: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 494.1-494.	0.5	0
31	AB0551â€¦Clinical Application of Two Different Disease Activity Scores for ENT Involvement in Granulomatosis with Polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1093.1-1093.	0.5	0
32	AB0589â€¦The role of anca specificity in the clinical manifestations at disease onset: comparison between patients with granulomatosis with polyangiitis and microscopic polyangiitis. , 2017, , .		0
33	FRI0310â€¦Long-term mortality and complications in young and elderly patients with anca-associated vasculitis. , 2017, , .		0
34	FRI0308â€¦Predictors of hypogammaglobulinaemia in rituximab treated patients. a retrospective analysis on a monocentric cohort. , 2017, , .		0
35	THU0328â€¦Predictors of severe damage in anca-associated vasculitis: data from a monocentric inception cohort. , 2017, , .		0
36	FRI0337â€¦Anca pattern in granulomatosis with polyangiitis and micropolyangiitis. a retrospective analysis on a multicentric inception cohort. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
37	OP0333â€¦Survival in anca associated vasculitides: a retrospective multicentric analysis in northern italy. , 2018, , .		0
38	THU0460â€¦Fully integrated 18f-fdg pet/mr in large vessel vasculitis. , 2018, , .		0
39	128.â€¦DISEASE AND TREATMENT-RELATED MORBIDITY AND COMPLICATIONS IN YOUNG AND ELDERLY PATIENTS WITH ANCA-ASSOCIATED VASCULITIS. Rheumatology, 2019, 58, .	0.9	0
40	039.â€¦ANTI-PENTRAXIN-3 AUTOANTIBODIES IN ANCA-ASSOCIATED VASCULITIS. Rheumatology, 2019, 58, .	0.9	0
41	242.â€¦1996 FIVE FACTOR SCORE VS 2009 REVISED FIVE FACTOR SCORE PROGNOSTIC VALUE IN A MULTICENTRIC COHORT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS PATIENTS. Rheumatology, 2019, 58, .	0.9	0
42	THU0290â€¦DISEASE AND TREATMENT-RELATED MORBIDITY IN YOUNG AND ELDERLY PATIENTS WITH ANCA-ASSOCIATED VASCULITIS. , 2019, , .		0
43	SAT0224â€¦PRESENTATION, MANAGEMENT AND OUTCOME OF ANCA ASSOCIATED VASCULITIDES IN ITALY: A 20-YEAR FOLLOW-UP STUDY. , 2019, , .		0
44	THU0311â€¦PERSISTENT LOW-GRADE VASCULAR INFLAMMATION IN LARGE VESSEL VASCULITIS: A LONGITUDINAL STUDY USING FULLY INTEGRATED 18F-FDG PET/MR. , 2019, , .		0
45	AB0700â€¦Is it feasible to withdraw immunosuppressive treatment in real-life patients with anca-associated vasculitis?. , 2018, , .		0
46	FRI0504â€¦Diffuse alveolar haemorrhage in anca-associated vasculitis: can we predict outcome? an italian multicentre retrospective long-term study of 102 patients. , 2018, , .		0
47	FRI0212â€¦THE ROLE OF AGE ON THE CLINICAL PRESENTATION AND RELAPSE RATES IN A LARGE COHORT OF 720 PATIENTS WITH GIANT CELL ARTERITIS. Annals of the Rheumatic Diseases, 2020, 79, 689.1-690.	0.5	0
48	FRI0214â€¦PERSISTENT LOW-GRADE FDG-PET VASCULAR INFLAMMATION IN REMITTED LVV-GCA PATIENTS IS ASSOCIATED TO A SIGNIFICANT HIGH RISK OF RELAPSE. Annals of the Rheumatic Diseases, 2020, 79, 690.2-691.	0.5	0
49	SAT0243â€¦SUBPHENOTYPES IN POLYARTERITIS NODOSA (PAN): TARGET ORGAN ASSOCIATIONS OF A WORLDWIDE COLLABORATION STUDY. Annals of the Rheumatic Diseases, 2020, 79, 1064-1065.	0.5	0
50	SAT0245â€¦RENAL INVOLVEMENT AT ONSET IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS: A MAJOR INDEPENDENT RISK FACTOR FOR RENAL RELAPSE. Annals of the Rheumatic Diseases, 2020, 79, 1065.2-1065.	0.5	0